Country Overviews: market research reports

... and pharmaceutical industry to reduce thefinancial burden of diseases, and the country's private healthcare sectors provide opportunities forforeign companies. However, the increasing drug rebate level has significantly undermined the profitsrecorded by generic drugmakers. The more ...  |  more...

... margins and introduced insecurityto an already difficult economic environment, and we continue to expect a contraction in the size of theHungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drugmakers will have tobecome even more ...  |  more...

... Portugal has already made considerable savings in the healthcaresectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients,changes to reference pricing, reductions in pharmacy margins and price cuts just some of ...  |  more...

... consumption is also expected to rise. However, financial inefficiencies within the healthinsurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet itsobligations on time, leaving patients to pay for formerly ...  |  more...

... by both NGOs and international investors as a sign that Zambia istaking its commitment to healthcare seriously. The country suffers from a burden of both communicableand non-communicable diseases, with a high incidence of HIV and ...  |  more...

... generic medicines, in tandem withprice-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake ofgeneric medicines will conspire to keep longer term growth steady, boosted by upward volume changes,with the patented drug market ...  |  more...

... centric initiative, and national electronic health records, plus the profile, comparative matrix and SWOT of the industry leading players: Parkway Holdings Ltd (Parkway), Thomson Medical Centre (TMC), Health Management International Ltd (HMI), and China Healthcare ...  |  more...

... believes the government needs to do more to alter patients' attitudestowards these drugs as this is the main growth deterrent. Headline Expenditure Projections Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% declinein ...  |  more...

... non-oil economies. Political risk remains elevated as many disputesbetween them are still unresolved. These macroeconomic uncertainties will mean lack of focus on publichealthcare provision, which further complicates the problem that the general population are unable ...  |  more...

... and the vast majority of expenditure will be on low-marginessential medicines. Due to tepid economic growth, our outlook for Gabon's pharmaceutical market isbelow that expected to be posted by many of its sub-Saharan Africa neighbours. ...  |  more...

... also experienced governmentcost containment policies and the patent cliff in Canada, the negative impact of these phenomena is lessextreme than that in many other developed countries. The average cost of generic drugs per prescriptionexperienced its ...  |  more...

... logistical challenges. In the short term, Kazakhstan's marketdevelopment is driven by a balanced policy of import substitution and integration into regional (CustomsUnion) and global (World Trade Organisation) systems. Over the longer term, the country could ...  |  more...

... and healthcare companies, it is unlikely that the gap inhealthcare provision will be filled by private healthcare firms. We continue to maintain that given therelatively small pharmaceutical and healthcare market in Botswana, we do not ...  |  more...